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The absence of biomarkers to accurately predict anticancer therapy
response remains a major obstacle in clinical oncology. We applied a gen-
ome-wide loss-of-function screening approach in human haploid cells to
characterize genetic vulnerabilities to classical microtubule-targeting agents.
Using docetaxel and vinorelbine, two well-established chemotherapeutic
agents, we sought to identify genetic alterations sensitizing human HAP1
cells to these drugs. Despite the fact that both drugs act on microtubules, a
set of distinct genes were identified whose disruption affects drug sensitiv-
ity. For docetaxel, this included a number of genes with a function in mito-
sis, while for vinorelbine we identified inactivation of FBXW7, RB1, and
NF2, three frequently mutated tumor suppressor genes, as sensitizing fac-
tors. We validated these genes using independent knockout clones and con-
firmed FBXW7 as an important regulator of the mitotic spindle assembly.
Upon FBXW7 depletion, vinorelbine treatment led to decreased survival of
cells due to defective mitotic progression and subsequent mitotic catastro-
phe. We show that haploid insertional mutagenesis screens are a useful tool
to study genetic vulnerabilities to classical chemotherapeutic drugs by iden-
tifying thus far unknown sensitivity factors. These results provide a ratio-
nale for investigating patient response to vinca alkaloid-based anticancer
treatment in relation to the mutational status of these three tumor suppres-
sor genes, and could in the future lead to the establishment of novel predic-
tive biomarkers or suggest new drug combinations based on molecular
mechanisms of drug sensitivity.
1. Introduction
Despite major advances in the treatment of dissemi-
nated cancers in recent years, treatment failure due to
drug resistance remains a major handicap in cancer
therapy. Unfortunately, there are even patients where
the chosen treatment is ineffective and primarily causes
side effects. Such unsuccessful treatments might result
in the accumulation of pan-resistant cancer cells and
patients might lose precious time. To avoid fruitless
treatments and instead provide the best regimen for an
individual patient, there is an urgent need for better
predictive markers which are designed to predict
whether a tumor will respond to a particular treatment
(Mehta et al., 2010). Known predictive markers
include BRCA1/2 mutations for PARP inhibitor
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treatment in breast and ovarian cancer (Bryant et al.,
2005; Farmer et al., 2005; Tutt et al., 2010), EGFR
mutations for tyrosine kinase inhibitors in non-small
cell lung cancer (Lynch et al., 2004; Maemondo et al.,
2010; Paez et al., 2004), and estrogen receptor status
for endocrine therapy of breast cancer (EBCTCG,
2005, Harris et al., 2007). However, these markers
cover only a small fraction of all cancer treatments
and patients. A better understanding of genetic vulner-
abilities in human cells could pave the way for the
identification of such biomarkers (Beijersbergen et al.,
2017; Fece de la Cruz et al., 2015).
During the course of treatment, many patients with
cancer receive chemotherapy which includes micro-
tubule-targeting agents (MTAs). MTAs suppress micro-
tubule dynamics by binding to tubulin, thereby targeting
proliferating cells (Stanton et al., 2011). Two major
classes of MTAs exist: microtubule-stabilizing drugs,
such as taxanes, and microtubule-destabilizing drugs,
such as vinca alkaloids. The former compounds bind to
tubulin subunits within polymerized microtubules, lead-
ing to a stabilization of the polymer and preventing its
depolymerization. In contrast, vinca alkaloids bind to
free tubulin, preventing the addition of free tubulin het-
erodimers to a growing microtubule and thereby promot-
ing its depolymerization. The effect on microtubule
stability is observed only at high drug concentrations,
however (Jordan and Wilson, 2004). The clinically more
relevant mode of action of these drugs is the suppression
of the microtubule’s dynamic turn over, inhibiting nor-
mal progression through mitosis which requires rapid
assembly and disassembly of microtubules and subse-
quently leading to aberrant mitosis or induction of apop-
tosis (Chen and Horwitz, 2002; Goncalves et al., 2001;
Hayden et al., 1990; Ngan et al., 2001).
In this study, we use docetaxel and the vinca alkaloid
vinorelbine as representative drugs of both MTA
classes. Docetaxel is approved by the U.S. Food and
Drug Administration for the treatment of head and
neck, gastric, breast, prostate, and non-small cell lung
cancer, and vinorelbine is approved for the treatment of
advanced non-small cell lung cancer [https://www.cance
r.gov/about-cancer/treatment/drugs/fda-docetaxel
and https://www.cancer.gov/about-cancer/treatment/
drugs/vinorelbinetartrate (last accessed 31.08.2017)].
Despite the frequent use of these antimitotic drugs, pri-
mary resistance is often encountered in the clinic, and
no established markers can predict MTA treatment
response in patients with cancer. To date, a number of
mechanisms for drug resistance have been described
including increased drug efflux, deregulated apoptotic
pathways, or mutations in the drug-binding domains of
tubulin subunits (O’Neill et al., 2011; Orr et al., 2003;
Szakacs et al., 2006). The clinical relevance of these
findings remains controversial, however, and they can-
not explain all cases of MTA resistance and therapy
failure (Borst, 2012; van Vuuren et al., 2015).
Recently, it has been shown that genome-wide inser-
tional mutagenesis screens in haploid cells can identify
novel mechanisms of resistance to classical anticancer
drugs like platinum salts or topoisomerase inhibitors (Pla-
nells-Cases et al., 2015; Wijdeven et al., 2015). In this
study, we applied an insertional mutagenesis-based
method to investigate gene essentiality and synthetic
lethality under conditions of MTA treatment. We com-
pared the potential vulnerabilities for both vinorelbine
and docetaxel and validated the loss of three clinically rel-
evant tumor suppressor genes (FBXW7, RB1, and NF2
(Valverde et al., 2005; Welcker and Clurman, 2008; Had-
field et al., 2010)) as sensitizing factors for vinorelbine.
Our study demonstrates that docetaxel and vinorel-
bine, although both acting on microtubules, differ in
the genetic vulnerabilities they exploit, and that muta-
tions frequently observed in patients with cancer could
potentially impact therapy response to a classical
chemotherapeutic drug. Furthermore, our study shows
that haploid insertional mutagenesis screens are useful
to search for genetic vulnerabilities to classical
chemotherapeutic drugs.
2. Materials and methods
2.1. Cell lines
HAP1 cells and knockout derivate cell lines were cul-
tured in IMDM medium containing 10% fetal bovine
serum, 1% penicillin-streptomycin, and 1 mM L-gluta-
mine (all reagents from Gibco, Thermo Fisher Scienti-
fic Inc., Waltham, MA, USA). Monoclonal knockout
cell lines were generated using CRISPR/Cas9 with the
following gRNA sequences: ABCB1: 50-TTGGCTTG
ACAAGTTGTATA-30; FBXW7: 50-AAATGAAGTC
TCGTTGAAAC-30; NF2: 50-CGTCACCATGGAC
GCCGAGA-30; RB1: 50-CAGTGTATCGGCTAGCC
TAT-30. At early passage, independent clones were iso-
lated from DNF2 and DRB1 and expanded as clone
(cln) 1 and 2. Successful generation of the monoclonal
knockout cells was confirmed by Sanger sequencing of
the DNA.
2.2. Haploid genetic screens
Gene-trap mutagenesis of wild-type HAP1 cells was per-
formed as described previously (Blomen et al., 2015). 108
mutagenized HAP1 cells were seeded in 14 T175 cell cul-
ture flasks (Corning, New York, NY, USA), treated 24 h
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after seeding with either 4.59 IC50 of docetaxel (7 nM,
Taxotere; Sanofi Aventis, Paris, France) or 6.59 IC50 of
vinorelbine (16 nM, Vinorelbine; Actavis, Luxembourg,
Luxembourg), as determined in nonmutagenized wild-
type HAP1 cells (see section 2.3). After 48-h (vinorelbine)
or 72-h (docetaxel) treatment, drug-containing medium
was removed and replaced with fresh medium without
drugs. On day 10, when cells displayed 70–80% conflu-
ency, cells were harvested and fixed in prewarmed BD
Phosflow fix buffer I (BD Bioscience, San Jose, CA,
USA) for 10 min at 37 °C. RNAse (Qiagen, Venlo, the
Netherlands) treatment (100 lgmL1) was performed at
37 °C for 1 h. Subsequently, cells were stained using
10 lgmL1 propidium iodide (Life Technologies, Carls-
bad, CA, USA), strained through a 40 lm cell strainer
(Falcon, Corning) before at least 30 million cells with 1n
DNA content were sorted on a Bio-Rad (Hercules, CA,
USA) S3 cell sorter. Genomic DNA isolation and linear
amplification mediated (LAM-)PCR were performed as
described in Blomen et al. (2015); as well as sequencing
data processing, insertion site mapping to GRCh37
human genome assembly, and subsequent analysis of
sense and antisense integrations. Four independent cul-
tured wild-type control datasets published in Blomen
et al. (2015), available at SRA (SRP058962, accession
numbers SRX1045464, SRX1045465, SRX1045466,
SRX1045467), were used for normalization. Drug-
selected screens were performed two times with individual
mutagenized HAP1 batches. Analysis criteria for the iden-
tification of sensitivity candidates were P = 0.01 with an
effect size cutoff = 1.2.
2.3. IC50 determination
A total of 3500 cells per well were seeded in 96-well
plates in triplicates and treated with increasing concen-
trations of docetaxel or vinorelbine after 24 h; 72 h
later, relative numbers of viable cells in comparison
with the untreated control were calculated after mea-
suring fluorescence intensity at 560Ex/590Em nm after
addition of Cell Titer Blue (Promega, Fitchburg, WI,
USA) on an Enspire Multimode Plate Reader (Perki-
nElmer, Waltham, MA, USA), normalized to solvent
control. Experiments were performed in three indepen-
dent replicates, and IC50 values were calculated using
GRAPHPAD PRISM software (GraphPad Software, San
Diego, CA, USA).
2.4. Drug titration experiments
Drug titrations were performed in 12-well plates, T25
and T175 flasks to find optimal screening conditions
using mutagenized HAP1 cells. Cells were seeded in
equal density as in the final screens, and drugs were
applied after 24 h of seeding. At day 10, wells were
fixed using 4% formalin and stained with 0.1% crystal
violet (Merck KGaA, Darmstadt, Germany). Quantifi-
cation was performed using ColonyArea Fiji plugin
(Guzman et al., 2014; Schindelin et al., 2012). Quan-
tification shown in Fig. S1 represents three indepen-
dent replicates of drug titrations, performed in
duplicates.
2.5. Validation experiments
Cells seeded in 12-well plates at equal density as in the
screens were treated after 24 h with either half, double,
or the same drug concentration as used in the screens
for 48 h (vinorelbine) or 72 h (docetaxel), or left
untreated. Untreated wells were fixed on day 5, drug-
treated wells on day 7 or 8. Cells were treated with vin-
cristine, vinblastine, or vindesine in an equal fashion as
with vinorelbine. A total of 4000 wild-type and 8000
FBXW7/ DLD1 cells were seeded in six-well plates,
treated after 24 h with the same vinorelbine concentra-
tions as have been used for HAP1 cells. After 48 h,
drug-containing medium was replaced by blank med-
ium and colony outgrowth was determined on day 9.
Experiments were repeated at least three times. Quan-
tification was performed as described in section 2.4.
2.6. Gene Ontology (GO) term analysis
Gene Ontology term analysis was performed using
string-db.org with 49 potentially sensitizing docetaxel
genes and 63 sensitizing vinorelbine genes (minimum
required interaction score = 0.4 with databases and co-
expression as interaction sources). GO terms were
ranked after false discovery rate (fdr) values and plot-
ted for log10(fdr).
2.7. Antibodies
Antibodies used in this study were as follows: mouse
Rb (4H1, 9309, dilution 1 : 1000), rabbit Nf2
(D3S3W, 12888, dilution 1 : 1000), rabbit C-myc
(9402, dilution 1 : 800), rabbit Aurora B/AIM1 (3094,
dilution 1 : 800), rabbit Mcl-1 (4572, dilution 1 : 800)
from Cell Signaling Technology, Cambridge, UK,
mouse a-Tubulin (DM1A, T9026, dilution 1 : 4000 for
western blotting and 1 : 500 for immunofluorescence
staining) and mouse b-Actin (A5441, dilution 1 : 4000)
from Sigma-Aldrich (St Louis, MO, USA), mouse
Cyclin B (05-373, dilution 1 : 1000) from Millipore
(Billerica, MA, USA), and mouse Aurora A
(BD610939, dilution 1 : 1000) from BD Bioscience. In-
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house antibodies against Cyclin E (HE-12, dilution
1 : 5) (Sonnen et al., 2013), Plk1 (36-298-4, dilution
1 : 5) (Yamaguchi et al., 2005), Mps1 (3-472-1, dilu-
tion 1 : 5) (Stucke et al., 2002), and BubR1 (68-3-9,
dilution 1 : 5) (Elowe et al., 2007) were described pre-
viously.
2.8. Western blotting
Cells were washed with PBS, lysed in RIPA buffer
(50 mM Tris/HCl pH 7.4; 1% NP-40; 0.5% Na-deoxy-
cholate; 0.1% SDS; 150 mM NaCl, 2 nM EDTA,
50 mM NaF) containing complete protease inhibitor
cocktail (Roche, F.Hoffmann-La Roche Ltd, Basel,
Switzerland) for 30 min on ice, and cleared by cen-
trifugation. Protein concentration was determined
using Pierce BCA assay kit (Thermo Fisher Scientific
Inc.) with a BSA standard curve. Before loading, pro-
tein lysates were denatured at 95 °C for 5 min in 69
SDS sample buffer. Proteins were separated by SDS/
PAGE on 7.5 or 10% gels before semi-dry transfer to
0.45 lm nitrocellulose membranes (GE Healthcare,
Chalfont St Giles, UK) and blocked in 5% dry milk
powder in TBS-T (100 mM Tris, pH 7.5, 0.9% NaCl,
0.05% Tween-20). Membranes were incubated with
primary antibodies diluted in 5% BSA in TBS-T at
4 °C over night. After washing in TBS-T, near-infra-
red labeled secondary antibodies (IRDye, Li-Cor Bios-
ciences, Lincoln, NE, USA, dilution 1 : 5000) were
applied for 4 h at room temperature. Images were
acquired using Azure c600 fluorescent imager.
Cells for protein extraction for western blots shown
in Figs 4C and S6 were synchronized in M phase using
5 lM S-Trityl-L-cysteine (Sigma-Aldrich) and harvested
by mitotic shake off before lysis in RIPA buffer.
2.9. qRT-PCR
RNA extraction was performed according to the
instructions of RNeasy Mini Kit (Qiagen), and cDNA
was reverse transcribed with reagents of Promega using
random primers. Quantitative PCR was performed
using Fast Start Universal SYBR Green Master (Rox)
(Roche, F.Hoffmann-La Roche Ltd,) on 96-well plates
in AB7500 real-time PCR cycler (Applied Biosystems,
Foster City, CA, USA). Forty cycles of 95 °C for 10 s
and 60 °C (FBXW7) or 58 °C (HRPT, MYC) for 30 s
after an initial preincubation at 95 °C for 10 min were
conducted. Primers were as follows: HPRT-forward:
GAAGAGCTATTGTAATGACC, HPRT-reverse: GC
GACCTTGACCATCTTTG, FBXW7-forward: GATA-
GAACCCCAGTTTCAACGAGAC, FBXW7-reverse: T
GGAGGCTCTCTGAGAGGTAACCC, MYC-forward:
TACCCTCTCAACGACAGCAG, MYC-reverse: CGT
CGAGGAGAGCAGAGAAT. The relative gene expres-
sion was calculated using the 2DDCt method.
2.10. FBXW7 rescue
As described in section 2.9, extracted RNA from HAP1
wild-type cells was reverse transcribed with reagents
from Promega using oligo(dT) primers. Primers to
amplify full-length cDNA of FBXW7 including restric-
tion enzyme sites were forward: CCGGAA
TTCCCACCATGAATCAGGAACTGCTCTCTGTG
GG and reverse: CGAGTCGACTTACTTCATGTC
CACATCAAAGTCCAGC. cDNA was amplified using
AccuPrime Taq High Fidelity Polymerase (Thermo
Fisher Scientific Inc.), and the corresponding band was
purified using QIAquick Gel Extraction kit (Qiagen)
before transformation into StrataClone TOPO vector
pSC-A-amp/kan (Agilent Technologies, Santa Clara,
CA, USA) according to the manufacturer’s protocol.
After purification, the pSC-A-amp/kan-FBXW7 and
empty pBABE vectors were digested using EcoR1 and
Sal1 enzymes (New England Biolabs, Ipswich, MA,
USA) for 1 h at 37 °C, followed by inactivation at
65 °C for 20 min. Ligation was performed using T4
DNA Ligase (New England Biolabs) with an insert to
vector ratio of 3 to 1 for 3 h at room temperature, fol-
lowed by an inactivation at 65 °C for 10 min, before
transformation into DH5a. Successful cloning of
pBABE-FBXW7 was confirmed by Sanger sequencing.
Fifty percent confluent phoenix retrovirus producer
cells were transfected with pBABE-FBXW7 or empty
pBABE using Turbofectin transfection reagent (Origene,
Rockville, MD, USA). The next day, virus-containing
supernatant was collected, filtered through a 0.45 lm fil-
ter before application to HAP1 DFBXW7 target cells
with Polybrene (Merck KGaA). Virus was harvested
and applied to target cells on three consecutive days.
1 lgmL1 Puromycin (Gibco) was used for selection to
generate stable HAP1 DFBXW7 pBABE-FBW7 and
HAP1 DFBXW7 pBABE cells.
2.11. Growth curve
Increasing numbers of the indicated cell lines were
seeded onto 96-well plates. After 3, 4, 5, and 6 days of
growth, their relative viability was measured as
described in section 2.3.
2.12. Reversine inhibitor experiments
A total of 5000 cells were seeded per well in 12-well
plates; 24 h later, indicated drug and Reversine (Enzo
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Biochem, New York, NY, USA) concentrations were
applied. At the indicated time points, fresh medium
with or without inhibitor was applied to the wells.
After 7 days, cells were fixed, stained, and quantified
as described in section 2.4. Experiments were repeated
three times.
2.13. FACS
For FACS analysis, diploid HAP1 wild-type and
DFBXW7 cells were subcloned. Cells were treated for
18 h with the indicated drug concentrations and fixed
in BD Phosflow fix buffer I at 37 °C for 10 min and
stained with DAPI (Invitrogen, Thermo Fisher Scienti-
fic Inc.) for 10 min at room temperature. The cell cycle
stages were analyzed on a BD LSR II Flow Cytometer
(blue/violet laser, filter 450/50). Data were processed
using FLOWJO software (FlowJo LLC, Ashland, OR,
USA) (n = 2).
2.14. Immunofluorescence staining
Cells were grown on coverslips, treated for 18 h with
the indicated drugs, and fixed with 4% formalin for
10 min at room temperature. Cells were permeabilized
in 0.2% Triton X-100, and antibodies, diluted in 10%
heat-inactivated FCS in PBS, were applied for 1 h at
room temperature. DNA was stained with DAPI
(Invitrogen) before mounting using DAKO mounting
media. Analysis was performed on a DeltaVision Elite
High Resolution Microscope system (GE Healthcare)
with Olympus IX-70 inverted microscope with a
CMOS camera, 1009 Olympus Objective, and SOFT-
WORX (Applied Precision, Issaquah, WA, USA) soft-
ware. Per condition, four times 16 adjacent image
fields were randomly taken for quantification. FIJI soft-
ware was used to process the images (Schindelin et al.,
2012).
2.15. Live cell imaging
Diploid cells were grown on 24-well plates and induced
with CellLight Histone 2B-GFP, BacMam 2.0
(Thermo Fisher Scientific Inc.) with PPC 50. The next
day medium was refreshed, and wells were washed sev-
eral times before the application of plain or drug-con-
taining medium. Three to 5 h later, live cell imaging
was performed for up to 24 h. Images were acquired
every ten minutes on the DeltaVision microscope with
a 409 Olympus Objective. FIJI software was used to
process the images. Time-lapse experiments have been
performed four times, and combined results of all
experiments are shown.
2.16. Correlation analysis
For the correlation of IC50 values with gene expres-
sion data from the Sanger 1001 cell line database, gene
expression data from GDSC (release 6.0) were used
(Yang et al., 2013). The log10[IC50] values were
retrieved from supplementary table 4A from Iorio
et al. (2016). Cell lines were clustered according to
GDSC tissue descriptor 2 and validated with matching
The Cancer Genome Atlas (TCGA) labels. Cell line
clusters with at least six members were taken into con-
sideration with a positive correlation and R2 ≥ 0.2.
Statistical analysis of correlation between vinorelbine
log10[IC50] and gene expression was performed by lin-
ear regression analysis with 95% confidence interval
where goodness of fit was defined by R2 using GRAPH-
PAD PRISM software (Version 7.01).
2.17. Statistical analysis
Statistical analysis was performed using GRAPHPAD
PRISM software (Version 6.05). Student’s unpaired
t-tests were employed as appropriate. ****P < 0.0001;
***P = 0.0001–0.001; **P = 0.001–0.01; *P = 0.01–
0.05, n.s. = not significant.
3. Results
3.1. Genome-wide loss-of-function screens in
human haploid HAP1 cells reveal genetic
vulnerabilities to microtubule-targeting agents
To identify genes whose loss mediates sensitivity of
cells to MTAs, we performed genome-wide loss-of-
function insertional mutagenesis screens in HAP1 cells
(Fig. 1A). We aimed for a drug selection causing a
mild fitness reduction of the cell population to main-
tain a high mutant library complexity. Based on short-
term cytotoxicity assays in which we initially deter-
mined the IC50 values of docetaxel and vinorelbine in
HAP1 cells (Fig. S1A), we titrated various docetaxel
and vinorelbine concentrations ranging between 2.5-
and 6.5-fold the IC50 (Fig. S1B). Treatment with 7 nM
docetaxel for 3 days or 16 nM vinorelbine for 2 days
resulted in the anticipated selection, and we subse-
quently used these conditions for the functional geno-
mic screens (Fig. S1C). For this purpose, we seeded
100 million gene-trap mutagenized cells and exposed
them to docetaxel or vinorelbine. At day 10, the sur-
viving cells were fixed and sorted for 1n DNA content,
to minimize the number of diploid cells carrying
heterozygous mutations. Gene-trap insertions were
identified by deep sequencing and subsequent mapping
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to the human genome. Four independently mutage-
nized wild-type HAP1 datasets (untreated) were used
as reference datasets for normalization (Blomen et al.,
2015). All unique integration events in the genome
were counted in the drug-selected and unselected data-
sets. The retroviral gene-trap cassette is unidirectional
and designed to disrupt gene function upon integration
in sense with the transcriptional orientation of the
gene (Fig. 1B). Because mutations in genes required
for fitness are detrimental to the cell, the proportion of
disruptive sense integrations in a particular gene can
be used as an estimate of essentiality. Comparing these
proportions in a gene of interest in both unselected
and drug-selected datasets enables the identification of
genes affecting cellular fitness specifically in the pres-
ence of the drugs: disruption of a gene not influencing
cellular fitness under these conditions will display an
approximate sense to antisense ratio of 0.5, reflecting
the expected gene-trap orientation ratio by chance.
Gene-inactivating mutations that result in a survival
benefit will have a ratio > 0.5, meaning more unique
disruptive sense integrations after the selection process.
Finally, loss of genes causing a fitness defect will score
with a ratio < 0.5, representing a loss of disruptive
sense integrations. Analysis of two independent repli-
cates for both docetaxel and vinorelbine identified sev-
eral genes whose disruptions potentially confer
hypersensitivity, and few genes potentially causing
resistance when inactivated (Table S1).
Loss of ABCB1, encoding for the multidrug efflux
transporter P-glycoprotein (P-gp), was identified as
one of the major sensitizing candidates in both
vinorelbine and docetaxel screens (Fig. 2A). Both
compounds are well-known substrates for P-gp (Borst,
2012; Szakacs et al., 2006), and we confirmed
increased sensitivity toward docetaxel and vinorelbine
using HAP1 cells deficient for ABCB1 (Fig. 2B). Thus,
the identification of loss of ABCB1 as a MTA sensi-
tizer shows that the screens identified genes that do
explain drug sensitivity.
Previous haploid screening approaches identified
gene disruptions that cause drug resistance by employ-
ing the density of individual disruptive gene-trap inte-
grations in a small pool of surviving cells as readout
(Planells-Cases et al., 2015; Wijdeven et al., 2015). As
opposed to this, the layout and analysis of our current
screens aimed at the identification of mutants that are
absent in the surviving pool and yielded therefore
potential genetic vulnerabilities. Applying stringent fil-
tering criteria, 49 genes that, if ablated, cause sensitiv-
ity with docetaxel and 63 genes with vinorelbine were
identified (Fig. 2C and Table S1). Of these, only 11
genes were shared among both treatment groups,
including ABCB1. As both drugs affect microtubule
dynamics and stability, we expected similar sensitivity
profiles in both datasets. However, the genetic vulnera-
bilities we found were rather distinct. Although both
drug screens yielded sensitizing genes associated with
the gene ontology term ‘cell cycle’, only the candidates
identified with docetaxel were enriched for ‘mitosis’ as
expected from the exposure to a spindle poison. Some
genes identified in the docetaxel screens, for example,
CCNB1, MAD1L1, MAD2L1, or KNTC1, all play
well-known roles during mitosis by contributing to a
Gene trap
mutagenesis
gDNA of 
3x107 1n HAP1 cells
16 nM vinorelbine
or
7 nM docetaxel
exon
1 2 SA GFP PA 3 4
exon
1 2
SAGFPPA
3 4
Sense integration → Disruped transcript Antisense integration → Normal transcript
ratio ≈ 0.5
ratio > 0.5
ratio < 0.5
Gene 1
Gene 2
Gene 3
Survival benefit
Neutral
Synthetic lethal
A
B
Fig. 1. Layout of the insertional mutagenesis haploid screens. (A) Wild-type HAP1 cells were gene-trap mutagenized, exposed to 16 nM
vinorelbine or 7 nM docetaxel, and subsequently allowed to recover until day 10. Genomic DNA of 3 9 107 cells with 1n DNA content was
extracted; insertion sites were amplified by LAM-PCR before sequencing, mapping to the human genome, and normalizing to untreated
cultured control datasets. Genes without effect on cellular fitness will have approximately equal numbers of disruptive sense and
nondisruptive antisense integrations (ratio 0.5, neutral gene). Genes in which mutations increase survival of the cell will score with a higher
proportion of sense integrations. Fewer sense integrations compared to antisense integrations will be counted in hypersensitivity genes.
(B) Illustrated in a simplified fashion, intronic gene-trap sense integration in relation to the transcriptional direction of a gene is disruptive,
whereas antisense integration does not affect the function of a transcript.
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Vinorelbine (nM)Docetaxel (nM)
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Fig. 2. Identification of ABCB1 validates the concept of the screens, while docetaxel and vinorelbine display different genetic vulnerabilities. (A)
Unique gene-trap insertions in ABCB1 in untreated (n = 4, left panel), docetaxel-treated (n = 2, panel in the center), and vinorelbine-treated
(n = 2, right panel) conditions. A representative example of each screening condition is shown including the P-value comparing the depicted
drug-treated replicate to the depicted untreated replicate, determined by Fisher’s exact t-tests. Y-axis represents the sense to antisense
integration ratio, while log10 of sense/total number of insertions is plotted on the x-axis. Loss of ABCB1 was neutral in regard to cell survival
without drug treatment, represented by a 0.5 sense to antisense ratio. Upon docetaxel or vinorelbine treatment, ABCB1 was depleted for
sense insertions (ratio < 0.5). (B) Validation of loss of ABCB1 as sensitizing factor for docetaxel and vinorelbine. Equal numbers of cells were
exposed to half, full, or twice the drug concentrations which have been used in the screens. Bar plots show mean quantification of three
biological replicates with SEM; **P = 0.001–0.01; *P = 0.01–0.05. (C) Venn diagram shows overlap between vinorelbine- and docetaxel-
sensitizing candidates of 11 genes; 38 genes, when inactivated, sensitize uniquely to docetaxel and 52 genes to vinorelbine. Bar plot shows
Gene Ontology enrichment analysis for biological processes of the sensitizing genes as log10 (fdr) values. Enrichment cutoff = 0.01.
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functional spindle assembly checkpoint (SAC) and
interact with each other (Schmit and Ahmad, 2007). In
contrast to the genes that sensitize to docetaxel upon
mutation, many of the vinorelbine candidates clustered
under ‘chromosome/organelle organization’. Intrigu-
ingly, we found FBXW7, RB1, two genes involved in
G1 cell cycle phase progression, and NF2 among the
genes which distinguished vinorelbine from docetaxel.
Inactivating mutations in these genes are frequently
found in various cancers and have been shown to con-
tribute to tumorigenesis (Akhoondi et al., 2007; Bur-
khart and Sage, 2008; Cheng and Li, 2012; Petrilli and
Fernandez-Valle, 2016). We therefore validated these
genes further.
3.2. Two clinically relevant tumor suppressor
genes, NF2 and RB1, show specific genetic
vulnerability to vinorelbine
The results of our screens indicate a sensitizing effect
of NF2 or RB1 loss for vinorelbine in HAP1 cells
(Fig. 3A). In the untreated controls, loss of NF2 indi-
cates a slight deficit in cellular fitness and loss of
RB1 at times gives a slight survival benefit. The same
observation was made in the docetaxel screens. In
contrast, both NF2 and RB1 sense integrations were
depleted under vinorelbine treatment. To validate this
finding, we tested two independent knockout clones
for both NF2 and RB1. In these, frameshift muta-
tions in the first (NF2) and in the 20th (RB1) exon
were introduced using CRISPR/Cas9. Successful
genetic ablation was confirmed by the absence of the
protein (Fig. 3B). DNF2 and DRB1 cells indeed dis-
played an increased sensitivity toward vinorelbine
and vincristine treatment in comparison with wild-
type HAP1 cells (Fig. 3C and S2D). For docetaxel
treatment, no significant effect on cellular survival
was observed subject to the inactivation of these two
genes, corroborating the results from the docetaxel
screens. Thus, we verified that inactivation of NF2 or
RB1 indeed caused hypersensitivity to vinorelbine in
HAP1 cells.
3.3. FBXW7 mutation is a novel genetic
vulnerability to vinorelbine
In addition to inactivation of NF2 and RB1, the E3 ubiq-
uitin ligase FBXW7 also scored as a sensitizing candidate
in the vinorelbine screens (Fig. 4A), whereas under stan-
dard culture conditions loss of FBXW7 causes a survival
benefit. To confirm this finding, we generated FBXW7-
deficient HAP1 cells, bearing a frameshift deletion in
exon 5 (shared by all three FBXW7 isoforms a, b, c),
using CRISPR/Cas9. Successful FBXW7 ablation was
confirmed by DNA sequencing (data not shown), qRT-
PCR (Fig. 4B) and by western blotting against cyclin E
(Fig. 4C), one of the ubiquitination substrates of
FBXW7 (Strohmaier et al., 2001). To verify the speci-
ficity of our observation, we reintroduced FBXW7 in
DFBXW7 cells, and the effective restoration was con-
firmed using the two latter assays. We found that dele-
tion of FBXW7 sensitizes HAP1 cells to vinorelbine,
vincristine, vinblastine, and vindesine and reintroduction
of FBXW7 cDNA restores the sensitivity back to wild-
type levels (Fig. 4D and S2A–C). This finding was fur-
thermore validated in the colorectal cancer cell line
DLD1 (Fig. S2E), in which exon 5 was deleted by homol-
ogous recombination (Rajagopalan et al., 2004). The
effect of FBXW7 loss on docetaxel sensitivity, however,
is only minor. This is also supported by the docetaxel
screens, where we did not identify FBXW7 as a signifi-
cant hit (Fig. 4A). The successful validation of FBXW7
ablation as a sensitizing determinant for vinorelbine was
somewhat unexpected, as a contribution to antitubulin
chemotherapeutic sensitivity has been attributed to
FBXW7 through ubiquitination of the anti-apoptotic
protein MCL-1 (Wertz et al., 2011). In the HAP1 cell
line, however, we did not observe an impact of FBXW7
loss or vinorelbine treatment on MCL-1 protein levels
(Fig. S3). We therefore propose an alternative, MCL1-
independent impact of FBXW7 loss on MTA treatment
response.
It is noteworthy that MYC, another ubiquitination
substrate of FBXW7 (Sato et al., 2015), is unaffected
at the mRNA and protein level by FBXW7 genotype
Fig. 3. NF2 and RB1 score as sensitizing candidates with vinorelbine. (A) Unique gene-trap insertions in NF2 and RB1 in untreated (n = 4, left
panel), docetaxel-treated (n = 2, panel in the center), and vinorelbine-treated (n = 2, right panel) conditions. A representative example of each
screening condition is shown including the P-value comparing the depicted drug-treated replicate to the depicted untreated replicate, determined
by Fisher’s exact t-tests. Y-axis represents the sense to antisense integration ratio, while log10 of sense/total number of insertions is plotted on
the x-axis. Loss of RB1 scored at times with a ratio > 0.5 in untreated and docetaxel-treated screens, indicating that disruptive sense integrations
caused a survival benefit. In vinorelbine screens, a ratio < 0.5 was observed for both RB1 and NF2. Noteworthy, loss of NF2 was of slight
disadvantage for survival even under untreated conditions, represented by a ratio < 0.5. (B) Confirmation of functional inactivation of NF2 and RB1
by western blotting with the respective antibodies (n = 2). (C) Validation of loss of NF2 and RB1 as sensitizing factor for vinorelbine with two
independent knockout clones each. Equal numbers of cells were exposed to half, full, or twice the drug concentrations which have been used in
the screens. Bar plots show mean quantification of three biological replicates with SEM; **P = 0.001–0.01; *P = 0.01–0.05.
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in HAP1 cells (Fig. S4). MYC has been ectopically
expressed while generating the HAP1 cell line (Carette
et al., 2011; Essletzbichler et al., 2014) and presumably
does not contribute to the observed phenotype.
DFBXW7 cells and wild-type HAP1 cells proliferate at
a similar rate under standard culture conditions
(Fig. S5). The sensitivity of FBXW7-deficient cells to
vinorelbine can therefore not be attributed to an
increased proliferation rate. We therefore evaluated other
potential mechanisms causing sensitivity to vinorelbine.
3.4. Inhibition of MPS1 overcomes the drug
sensitivity in DFBXW7 cells
To elucidate the underlying mechanism of increased
sensitivity upon FBXW7 depletion, we hypothesized
that the spindle assembly checkpoint might be
involved due to a recently described link between
FBXW7 and the SAC (Bailey et al., 2015). To test this,
we inhibited the essential spindle assembly checkpoint
kinase MPS1 using reversine. Inhibiting MPS1 causes
mitotic progression despite improper chromosome
alignment during metaphase (Hiruma et al., 2016; San-
taguida et al., 2010). Reversine treatment for 24 h sig-
nificantly de-sensitized DFBXW7 cells to vinorelbine
(Fig. 5A) only after vinorelbine and not docetaxel
treatment (Fig. S6). Prolonged exposure to reversine
for 120 h decreased survival of both FBXW7-proficient
and FBXW7-deficient cells, however. Hence, the sensi-
tivity of DFBXW7 cells to vinorelbine can temporarily
be blocked by inhibiting an essential component
required for proper cell division.
To further examine potential cell cycle alterations,
we selected diploid HAP1 clones and analyzed their
cell cycle distribution upon treatment. HAP1 cells can
turn diploid during passaging or treatment through
endoreduplication events (Essletzbichler et al., 2014)
and diploid clones are more appropriate for cell cycle
analysis using flow cytometry, as it is difficult to dis-
tinguish haploid G2/M from diploid G1 populations.
Like the haploid cells, diploid DFBXW7 cells showed
increased vinorelbine sensitivity compared to diploid
wild-type cells (data not shown). When we investigated
the cell cycle distribution, we found that wild-type cells
tolerated a dose of 1.39 IC50 of vinorelbine for 18 h,
whereas DFBXW7 cells shifted toward G2/M and
polyploidy (Fig 5B). These cells also showed an
increase in cell size throughout all cell cycle stages
(data not shown). In contrast, exposing wild-type or
DFBXW7 cells to 1.39 IC50 of docetaxel did not yield
a significant impact on the cell cycle profile. To assess
whether DFBXW7 cells have an altered mitotic regula-
tion, we examined some mitotic regulatory proteins by
western blotting analysis of mitotic cells. We observed
increased levels of CYCLIN B, MPS1, PLK1, BUBR1,
AURORA A, and AURORA B in DFBXW7 cells
compared to wild-type cells (Fig. S7). This is in agree-
ment with the dependence of FBXW7-deficient cells on
a functional spindle assembly checkpoint and the
involvement of FBXW7 in AURORA B degradation
(Bailey et al., 2015; Teng et al., 2012). Treatment with
vinorelbine had no additional impact on protein levels.
3.5. Vinorelbine exposure reduces the number of
mitotic DFBXW7 cells and causes increased
multinucleation and mitotic cell death
To distinguish whether the >G2/M population
observed in the FACS experiments contains arrested
mitotic cells or polyploid/multinucleated cells, we
assessed the frequency of cells in mitosis after 18-h
treatment with 0.89 IC50 of vinorelbine or docetaxel
by antitubulin immunofluorescence staining. Com-
pared to vinorelbine-treated wild-type cells, signifi-
cantly fewer DFBXW7 cells were found in mitosis
(Fig. 6A). For docetaxel treatment, no significant dif-
ference in the proportion of mitotic cells in the three
genotypes was observed.
To further decipher the mitotic alterations, we moni-
tored GFP-tagged H2B DFBXW7 and wild-type cells
Fig. 4. Identification of FBXW7 mutation as a genetic vulnerability to vinorelbine. (A) Unique gene-trap insertions in FBXW7 in untreated
(n = 4, left panel), docetaxel-treated (n = 2, panel in the center), and vinorelbine-treated (n = 2, right panel) conditions. A representative
example of each screening condition is shown including the P-value comparing the depicted drug-treated replicate to the depicted
untreated replicate, determined by Fisher’s exact t-tests. Y-axis represents the sense to antisense integration ratio, while log10 of
sense/total number of insertions is plotted on the x-axis. Loss of FBXW7 scored with a ratio > 0.5 in untreated conditions and
docetaxel-treated screens, indicating that disruptive sense integrations caused a survival benefit. For vinorelbine treatment, loss of
FBXW7 resulted in a disadvantage for survival, represented by a ratio < 0.5. (B) Confirmation of functional inactivation and restoration
of FBXW7 mRNA relative to HPRT (n = 3) and by (C) western blotting against CYCLIN E, a target of FBXW7-mediated degradation
(n = 3). (D) Validation of loss of FBXW7 as sensitizing factor for vinorelbine. Restoration of FBXW7 in DFBXW7 cells reduced the
sensitivity to vinorelbine close to wild-type levels. Equal numbers of cells were exposed to half, full, or twice the drug concentrations
which have been used in the screens. Bar plots show mean quantification of three biological replicates with SEM; ***P = 0.0001–
0.001; **P = 0.001–0.01; *P = 0.01–0.05.
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Fig. 6. Less DFBXW7 cells are in mitosis after 18 h of vinorelbine treatment. Representative images of antitubulin immunofluorescence
staining after 18 h of treatment with 0.89 IC50 of vinorelbine or docetaxel. Cells in prometaphase to anaphase stage of mitosis, indicated
with arrows, were counted in 49 16 adjacent 1009 power fields as percentage of total number of cells. Scale bar represents 10 lm.
Mitotic cells in the three indicated cell lines, normalized to percentage of mitotic cells without treatment, of one experiment are quantified
in the bar blot with SD. Note the significant lower number of mitotic cells in the DFBXW7 cell line. *P = 0.01–0.05, n.s. = not significant,
n = 2.
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by time-lapse microscopy. Treatment with vinorelbine
or docetaxel IC50 concentrations caused a significantly
prolonged mitosis in both wild-type and DFBXW7
cells (Fig. 7A). In DFBXW7 cells, vinorelbine treat-
ment resulted in a significantly extended time interval
from entry into prometaphase until the metaphase
plate was formed compared to wild-type cells, while
the interval from metaphase to anaphase is signifi-
cantly reduced. A prolonged mitotic arrest is expected
upon vinorelbine treatment (Jordan et al., 1998; Ngan
et al., 2001), and we observed that wild-type cells are
able to correct the mitotic defects more frequently and
undergo cell divisions resulting in viable daughter cells.
In DFBXW7 cells, the treatment effects are much more
severe: Whereas wild-type cells are able to repeatedly
enter metaphase until all chromosomes are aligned,
DFBXW7 cells more frequently exit mitosis as multinu-
cleated cells or died in the course of (repeated or sin-
gle) metaphase formation (Fig. 7B). Docetaxel
treatment, in contrast, mostly resulted in an increased
number of multipolar spindle configurations, which
was tolerated by both genotypes. Our results indicate
that DFBXW7 cells are unable to overcome destabiliz-
ing disturbances of the mitotic spindle caused by
vinorelbine which drives the cells into mitotic catastro-
phe. Thus, DFBXW7 cells are more effectively killed
by vinca alkaloid treatment.
3.6. Low FBXW7 gene expression correlates
significantly with increased vinorelbine
sensitivity in cell lines derived from lymphoid,
thyroid, and pancreatic tumors
We next investigated whether there may be specific
tumor types for which FBXW7 could potentially serve
as a useful predictive marker of vinorelbine response.
For this purpose, we tested whether there is a positive
correlation between FBXW7 gene expression and
vinorelbine sensitivity (log10[IC50] values) in the San-
ger cell line dataset (Iorio et al., 2016). Using tissue
clusters for which at least six independent cell lines
were treated with vinorelbine, we found a positive cor-
relation with R2 ≥ 0.2 for five tumor types (‘lymphoid
neoplasm other’, ‘lymphoblastic T cell leukemia’,
‘Non-small cell lung cancer not specified’, ‘pancreas’,
and ‘thyroid’) (Fig. S8A, C). Of these, linear regression
analysis showed a significant correlation (P < 0.05) for
‘lymphoid neoplasm other’, ‘thyroid’, and ‘pancreas’.
Regarding the positive correlation between RB1 gene
expression and vinorelbine IC50 values, we identified
four tissue clusters with at least six cell lines to be pos-
itively correlated with an R2 ≥ 0.2. Of these, ‘en-
dometrium’, ‘cervix’, and ‘lymphoid neoplasm other’
were significant (Fig. S8B, D). For NF2, we did not
find a tumor type with a significant correlation using
the available resources (data not shown). Thus, the
study of the Sanger cell line dataset supports the corre-
lation between vinorelbine sensitivity and low FBXW7
or RB1 expression in tumor cell lines derived from
specific tissues.
4. Discussion
In this study, we leveraged negative selection in mutag-
enized haploid cells to detect genetic vulnerabilities
between genes and chemotherapeutic compounds on a
genome-wide scale. Using loss-of-function insertional
mutagenesis screens, we identified several genes whose
genetic inactivation sensitizes cells to MTAs. Although
the mutational landscape found in patients is highly
complex and gene-trap-mediated gene disruption does
not reflect this entire spectrum, loss-of-function screen-
ing approaches are useful to gain better mechanistic
insight into the problem of drug resistance. It is well
known that both drugs, vinorelbine and docetaxel, are
transported by P-gp, and it is expected that ABCB1-
mutated cells have a survival handicap when they are
exposed to these drugs. We furthermore anticipated
genes around the mitotic cell cycle for both MTA
screens, as inhibition of microtubule dynamics is most
harmful during mitosis. For docetaxel, we indeed
found a considerable number of mitotic genes, indicat-
ing that docetaxel treatment more efficiently kills cells
when genes involved in mitotic regulation, in particu-
lar the spindle assembly checkpoint, are mutated.
However, the genetic mutations sensitizing to vinorel-
bine that we identified have thus far not directly been
linked to mitosis. Among these genes, we identified
two genes involved in regulation of G1 cell cycle
phase, FBXW7 and RB1 (Goodrich et al., 1991; Wel-
cker and Clurman, 2008). Up to 6% of all human can-
cers bear mutations in FBXW7 (Akhoondi et al.,
2007), and RB1 alterations occur in about 60–90% of
sporadic small cell lung cancer cases, for instance
(George et al., 2015). To our knowledge, it has not
been shown thus far that loss-of-function mutations in
FBXW7 or RB1 sensitize cells to vinca alkaloids. How-
ever, there are a few reports suggesting that vinca
alkaloids induce a postmitotic G1 arrest, rather than a
mitotic G2/M arrest (Ehrhardt et al., 2013; Pourroy
et al., 2004). Moreover, we identified the disruption of
another tumor suppressor gene with a microtubule-sta-
bilizing function, described already, NF2 (Smole et al.,
2014), as a specific vulnerability to vinorelbine.
Previously, it has been shown that downregulation
of FBXW7 was associated with antitubulin drug
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resistance due to increased levels of the anti-apoptotic
protein MCL-1 (Wertz et al., 2011). In the HAP1 cell
line, we did not observe a dependence of MCL-1 pro-
tein levels on FBXW7 genotype or vinca alkaloid treat-
ment, however. HCT116 cells, used by Wertz et al.
(2011), seem to be rather insensitive to MTAs com-
pared to HAP1 cells, as treatment with 1 lM for 48 h
still resulted in approximately 30% viability of cells. In
another study using the same cell lines, no resistance
to low concentrations of the spindle poisons nocoda-
zole or paclitaxel was observed (Bailey et al., 2015).
Hence, we suggest a MCL-1-independent effect of
FBXW7-mediated vinca alkaloid sensitivity at low
drug concentration.
Inhibition of the spindle assembly checkpoint using
reversine could temporarily protect DFBXW7 cells
from vinorelbine hypersensitivity. This observation
confirms a previously reported dependence of FBXW7-
mutated cells on a functional SAC (Bailey et al., 2015)
and supports the involvement of mitotic control mech-
anisms in FBXW7-dependent vinorelbine sensitivity in
HAP1 cells. We observed that protein levels of mitotic
regulators are increased upon FBXW7 deletion, pro-
viding more evidence for the role of FBXW7 as a reg-
ulator of mitotic processes (Teng et al., 2012). This is
further supported by the increase of polyploidy and
multinucleation in FBXW7-deficient cells exposed to
vinorelbine. Furthermore, a large proportion of
FBXW7-deficient cells died in the course of mitosis,
explaining why we found less mitotic FBXW7-deficient
cells upon treatment. Taken together, our results sug-
gest that upon FBXW7 loss and vinorelbine exposure,
cells more frequently fail to undergo regular mitosis,
leading to mitotic death or polyploidy and multinucle-
ation. We therefore hypothesize that FBXW7-mutated
tumors may benefit more from vinca alkaloid-based
MTA treatment than from taxanes and provide a
rationale for MTA drug response exploration in vivo.
Furthermore, our data indicate that vinca alkaloid
treatment could be more effective when cells lack a
functional G1 checkpoint, causing a stronger depen-
dence on a functional SAC and providing a potential
drug combination window for further exploration.
Our data show that two drugs targeting tubulin display
different genetic vulnerabilities in HAP1 cells, indicating
that their chemical–genetic interactions and cellular
effects might still not have been entirely deciphered
despite their longstanding clinical use. We expect that our
study will provide new mechanistic insights into cellular
therapy sensitivity which in the future can hopefully be
leveraged to optimize microtubule-targeting chemother-
apy for patients with cancer. Unfortunately, clinical data
for vinorelbine-treated patients including gene expression
and survival data are rare. However, the correlation anal-
ysis between vinorelbine sensitivity and gene expression in
the Sanger cell line panel yielded specific types of tumors
on which future analyses might be focused. To explore
the potential of our findings as predictive biomarker for
vinorelbine treatment, such a clinical study would be
essential.
Previous attempts to find predictive genetic signatures
for classical cytotoxic chemotherapy, for instance by cor-
relating gene expression of cell lines to IC50 values with-
out functional validation, yielded irreproducible results
(Baggerly and Coombes, 2009). Some signatures based on
patient data are, after many years, still not clinically vali-
dated (Chang et al., 2003; Chibon, 2013). So far, predic-
tions have only confirmed where the therapeutic target is
biologically validated, as the BRCA1/2 PARP inhibitor
example. Genome-wide functional genomic screens pro-
vide an alternative to the in silico approaches and a pow-
erful tool to identify genetic contributions to therapy
response (Planells-Cases et al., 2015; Steinhart et al.,
2017; Tzelepis et al., 2016; Wijdeven et al., 2015). In an
unbiased fashion, new genetic vulnerabilities of human
cells to anticancer drugs can be uncovered. In our current
study, we addressed drug sensitivity to classical MTAs,
compounds that are still standard of care for many
patients. These findings can now be translated into several
cancer models and might contribute to our current reper-
toire of therapy response prediction and to a better under-
standing of the mode of action of these cytotoxic
compounds.
5. Conclusion
In summary, our results indicate that haploid insertional
mutagenesis screens are a valuable tool to study drug
sensitivity. Understanding genetic vulnerabilities will be
of help to optimize cancer treatment, and we present
here one approach to unveil hypersensitivity to a classic
chemotherapeutic drug. This could lead to the establish-
ment of novel predictive biomarkers, result in new drug
combinations, and provide deeper insight into basic bio-
logical processes of these compounds. We demonstrate
that genetic vulnerabilities to classical anticancer drugs
exist and that this approach gives robust results which
could be confirmed using independent knockouts. We
hope that our data serves as a starting point to further
examine cancer vulnerabilities, in particular in FBXW7-,
RB1-, or NF2-mutated tumors.
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